135 related articles for article (PubMed ID: 31850205)
1. The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.
Rødland GE; Melhus K; Generalov R; Gilani S; Bertoni F; Dahle J; Syljuåsen RG; Patzke S
Front Oncol; 2019; 9():1301. PubMed ID: 31850205
[TBL] [Abstract][Full Text] [Related]
2.
Malenge MM; Patzke S; Ree AH; Stokke T; Ceuppens P; Middleton B; Dahle J; Repetto-Llamazares AHV
J Nucl Med; 2020 Oct; 61(10):1468-1475. PubMed ID: 32245896
[TBL] [Abstract][Full Text] [Related]
3. Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
Blakkisrud J; Løndalen A; Dahle J; Turner S; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):55-61. PubMed ID: 27587710
[TBL] [Abstract][Full Text] [Related]
4. FDG PET/CT and Dosimetric Studies of
Løndalen A; Blakkisrud J; Revheim ME; Dahle J; Kolstad A; Stokke C
Mol Imaging Biol; 2022 Oct; 24(5):807-817. PubMed ID: 35486292
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic effectiveness of
Pichard A; Marcatili S; Karam J; Constanzo J; Ladjohounlou R; Courteau A; Jarlier M; Bonnefoy N; Patzke S; Stenberg V; Coopman P; Cartron G; Navarro-Teulon I; Repetto-Llamazares A; Heyerdahl H; Dahle J; Bardiès M; Pouget JP
Leukemia; 2020 May; 34(5):1315-1328. PubMed ID: 31836849
[TBL] [Abstract][Full Text] [Related]
6. Pre-dosing with lilotomab prior to therapy with
Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
[TBL] [Abstract][Full Text] [Related]
7. Combination of
Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
Blakkisrud J; Løndalen A; Martinsen AC; Dahle J; Holtedahl JE; Bach-Gansmo T; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):48-54. PubMed ID: 27493270
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
Blakkisrud J; Holtedahl JE; Løndalen A; Dahle J; Bach-Gansmo T; Holte H; Nygaard S; Kolstad A; Stokke C
J Nucl Med; 2018 Apr; 59(4):704-710. PubMed ID: 28848035
[No Abstract] [Full Text] [Related]
10. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Kolstad A; Illidge T; Bolstad N; Spetalen S; Madsbu U; Stokke C; Blakkisrud J; Løndalen A; O'Rourke N; Beasley M; Jurczak W; Fagerli UM; Kaščák M; Bayne M; Obr A; Dahle J; Rojkjaer L; Pascal V; Holte H
Blood Adv; 2020 Sep; 4(17):4091-4101. PubMed ID: 32877524
[TBL] [Abstract][Full Text] [Related]
11. Myelosuppression in patients treated with
Blakkisrud J; Løndalen A; Dahle J; Martinsen AC; Kolstad A; Stokke C
Acta Oncol; 2021 Nov; 60(11):1481-1488. PubMed ID: 34425735
[TBL] [Abstract][Full Text] [Related]
12. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
13. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
[TBL] [Abstract][Full Text] [Related]
14. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Li J; Qian C; Zhou Q; Li J; Li K; Yi P
Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
[TBL] [Abstract][Full Text] [Related]
15. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY
Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766
[TBL] [Abstract][Full Text] [Related]
16. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
17. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
19. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
20. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
